Implementing long-acting injectable HIV PrEP: Recommendations to support the Australian health sector
On the 6th of April 2024, ASHM Health organised a national workshop, funded by ViiV Healthcare, to convene a select group of key stakeholders from each Australian state and territory. The primary objective was to facilitate discussions around how to successfully implement the use of long-acting injectable cabotegravir (CAB-LA) as HIV PrEP throughout Australia and to identify […]
Medications used for HIV Pre-Exposure Prophylaxis (PrEP) experiencing supply shortages in Australia
As of 9 September 2024, Australia is currently experiencing a supply shortage of medications containing tenofovir and emtricitabine, which are commonly used for HIV Pre-Exposure Prophylaxis (PrEP). Despite this shortage, pharmacists, HIV PrEP prescribers, and people using HIV PrEP should not be alarmed — shortages are expected to resolve later this year for most brands. Current impact […]
How co-design is revolutionising hepatitis B care in the Northern Territory
When studying the genotype of chronic hepatitis B (CHB) in the Northern Territory (NT), researchers discovered that 100% of CHB in Aboriginal and Torres Strait Islander peoples in the NT is due to the unique sub-genotype C4 , which is associated with quicker progression to liver cancer and cirrhosis. “It upped the urgency for us […]
Remote prescribing breaking down barriers to hepatitis C treatment in New South Wales
Hepatitis C is curable in most people. Hepatitis C treatment in the form of direct-acting antiviral medicines (DAAs) can cure more than 95% of people living with hepatitis C. While the number of people living with hepatitis C is decreasing overall, the cumulative proportion of people living with hepatitis C initiating DAA treatment remains lower […]
Trust imperative for reaching multicultural communities with hepatitis B care
In Australia, chronic hepatitis B disproportionately affects people born overseas. More than two-thirds of those living with the infection were born overseas or are Aboriginal and Torres Strait Islander people. It is therefore vital that hepatitis B programs, services and care are culturally appropriate and safe. If Australia is to reach its hepatitis B treatment […]
Stigma and discrimination, no place in healthcare.
Stigma and discrimination, no place in healthcare. These resources serve as a guide and support for healthcare professionals seeking to understand and address the impact of stigma and discrimination on patient care. Our materials cover best practices for creating inclusive healthcare environments, identification and mitigation of bias, and relevant research and literature on the topic. […]
NSW Hepatitis C Remote Prescribing Program
The NSW Hepatitis C Remote Prescribing Program was established in November 2020 to facilitate linkages between nurses who perform the patient assessment and medical practitioners/nurse practitioners who initiate hepatitis C treatment. The program aims to increase access to hepatitis C treatment in NSW in regional areas and other settings where treatment may be limited. Further […]
